Monitor TRANSCEND Phase 3 readout in H1 2027 for felzartamab as a potential pipeline catalyst. The EMPAVELI label expansion is already priced in; this ASN update is incremental and unlikely to move the stock.
Price Chart
Executive Summary
Biogen is presenting new 76-week EMPAVELI data at ASN Kidney Week showing sustained proteinuria reduction and continued eGFR stabilization in C3G and primary IC-MPGN, following the recent FDA label expansion to include reducing loss of kidney function. The company is also highlighting its investigational anti-CD38 antibody felzartamab across multiple immune-mediated kidney diseases, with Phase 3 data from the TRANSCEND study expected in H1 2027. This is a routine scientific conference update with no new regulatory or financial catalysts.
Key Facts
- New 76-week EMPAVELI data shows sustained proteinuria reduction and continued eGFR stabilization in C3G and primary IC-MPGN.
- FDA recently expanded EMPAVELI's indication to include reducing loss of kidney function in C3G and primary IC-MPGN.
- Felzartamab is in three Phase 3 trials: TRANSCEND (AMR), PREVAIL (IgA nephropathy), PROMINENT (primary membranous nephropathy), and a Phase 2 trial in microvascular inflammation.
- TRANSCEND Phase 3 data expected in H1 2027.
- Biogen's nephrology portfolio now spans seven different kidney diseases.
Financial Impact
No financial figures disclosed; EMPAVELI already approved and generating revenue. Felzartamab is investigational with no near-term revenue impact.
Risk Factors
- Felzartamab is investigational and may fail in Phase 3 trials.
- EMPAVELI carries a boxed warning for serious encapsulated bacterial infections, which could limit adoption.
- Competition from other complement inhibitors in C3G and IC-MPGN.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383328 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $233.48 | awaiting T+60 | — | $251.47 (+7.71%) |
Oct 12, 2026 15d ago | ANALYST-UPGRADE | $229.41 | awaiting T+60 | — | $251.47 (+9.62%) |
Oct 2, 2026 25d ago | Press Release | $219.88 | awaiting T+60 | — | $251.47 (+14.37%) |
Sep 17, 2026 5w ago | Press Release | $215.50 | awaiting T+60 | — | $251.47 (+16.69%) |
Sep 3, 2026 7w ago | Press Release | $220.83 | awaiting T+60 | — | $251.47 (+13.87%) |
Sep 3, 2026 7w ago | Press Release | $224.51 | awaiting T+60 | — | $251.47 (+12.01%) |
Aug 6, 2026 11w ago | Press Release | $207.94 | awaiting T+60 | — | $251.47 (+20.93%) |
Jul 14, 2026 15w ago | Press Release | $191.95 $222.15 | ▲ +15.73% | ▲ +12.36% | $251.47 (+31.01%) |
Jul 13, 2026 15w ago | Press Release | $191.95 $222.15 | ▲ +15.73% | ▲ +12.36% | $251.47 (+31.01%) |
Jul 13, 2026 15w ago | ANALYST-UPGRADE | — | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers